RDUS
$18.56
Radius Health
($.29)
(1.54%)
RDUS
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.76)
Revenue:  $52.29 Mil
Thursday
Feb 27
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RDUS reports earnings?
Beat
Meet
Miss

Where is RDUS's stock price going from here?
Up
Flat
Down
Stock chart of RDUS
Analysts
Summary of analysts' recommendations for RDUS
Score
Grade
Pivots
Resistance
$19.95
$19.51
$19.18

$18.74

Support
$18.41
$17.97
$17.64
Tweet
Growth
Description
Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company's lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.
Peers
Regeneron PharmaceuticalsBioMarin PharmaceuticalInterCeptVertex PharmaceuticalsMylanZoetisJohnson & JohnsonUltragenyx PharmaceuticalBristol-Myers SquibbEndo International plc